Want to join the conversation?
During 3Q16, in $A's life sciences market, pharma posted core revenue growth of 10%. Academia and government core revenues were down 5% and down across most geographies except China. Clinical and diagnostics grew 4% with strength in North America and Asia.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.